Human intestinal P‐glycoprotein activity estimated by the model substrate digoxin

References

• Andersen V., Pedersen N., Larsen N. E., Sonne J., Larsen S. Intestinal first pass metabolism of midazolam in liver cirrhosis: effect of grapefruit juice. Br J Clin Pharmacol 2002; 54: 120–4
   PubMed Web of Science ®Google Scholar
• Greiner B., Eichelbaum M., Fritz P., Kreichgauer H. P., von Richter O., Zundler J., et al. The role of intestinal P‐glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147–53
   PubMed Web of Science ®Google Scholar
• Taniguchi S., Mochida Y., Uchiumi T., Tahira T., Hayashi K., Takagi K., et al. Genetic polymorphism at the 5′ regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon. Mol Cancer Ther 2003; 2: 1351–9
   PubMed Web of Science ®Google Scholar
• Ieiri I., Takane H., Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 2004; 43: 553–76
   PubMed Web of Science ®Google Scholar
• Chowbay B., Li H., David M., Bun C. Y., Lee E. J. Meta‐analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 2005; 60: 159–71
   PubMed Web of Science ®Google Scholar
• Abu‐Qare A. W., Elmasry E., Abou‐Donia M. B. A role for P‐glycoprotein in environmental toxicology. J Toxicol Environ Health B Crit Rev 2003; 6: 279–88
   PubMed Web of Science ®Google Scholar
• Marzolini C., Paus E., Buclin T., Kim R. B. Polymorphisms in human MDR1 (P‐glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75: 13–33
   PubMed Web of Science ®Google Scholar
• Bilsborough J., Viney J. L. Out, out darn toxin: the role of MDR in intestinal homeostasis. Gastroenterology 2004; 127: 39–40
   Google Scholar
• Yacyshyn B., Maksymowych W., Bowen‐Yacyshyn M. B. Differences in P‐glycoprotein‐170 expression and activity between Crohn's disease and ulcerative colitis. Hum Immunol 1999; 60: 677–87
   PubMed Web of Science ®Google Scholar
• Panwala C. M., Jones J. C., Viney J. L. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998; 161: 5733–44
   PubMed Web of Science ®Google Scholar
• Schwab M., Schaeffeler E., Marx C., Fromm M. F., Kaskas B., Metzler J., et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003; 124: 26–33
   PubMed Web of Science ®Google Scholar
• Brant S. R., Panhuysen C. I., Nicolae D., Reddy D. M., Bonen D. K., Karaliukas R., et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet 2003; 73: 1282–92
   PubMed Web of Science ®Google Scholar
• Gazouli M., Zacharatos P., Gorgoulis V., Mantzaris G., Papalambros E., Ikonomopoulos J. The C3435T MDR1 gene polymorphism is not associated with susceptibility for ulcerative colitis in Greek population. Gastroenterology 2004; 126: 367–9
   PubMed Web of Science ®Google Scholar
• Langmann T., Moehle C., Mauerer R., Scharl M., Liebisch G., Zahn A., et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 2004; 127: 26–40
   PubMed Web of Science ®Google Scholar
• Potocnik U., Glavac M. R., Golouh R., Glavac D. The role of P‐glycoprotein (MDR1) polymorphisms and mutations in colorectal cancer. Pflugers Arch 2001; 442: R182–3
   PubMed Web of Science ®Google Scholar
• Johnstone R. W., Ruefli A. A., Smyth M. J. Multiple physiological functions for multidrug transporter P‐glycoprotein?. Trends Biochem Sci 2000; 25: 1–6
   PubMed Web of Science ®Google Scholar
• Jones S. A., Moore L. B., Shenk J. L., Wisely G. B., Hamilton G. A., McKee D. D., Tomkinson N. C., et al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 2000; 14: 27–39
   PubMed Web of Science ®Google Scholar
• Lee C. H., Ling V. Superinduction of P‐glycoprotein messenger RNA in vivo in the presence of transcriptional inhibitors. J Exp Ther Oncol 2003; 3: 14–26
   PubMedGoogle Scholar
• Litman T., Druley T. E., Stein W. D., Bates S. E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001; 58: 931–59
   PubMed Web of Science ®Google Scholar
• Olesen L. H., Norgaard J. M., Pallisgaard N., Bukh A., Hokland P. Validation and clinical implication of a quantitative real‐time PCR determination of MDR1 gene expression: comparison with semi‐quantitative PCR in 101 patients with acute myeloid leukemia. Eur J Haematol 2003; 70: 296–303
   PubMed Web of Science ®Google Scholar
• Jamroziak K., Balcerczak E., Mlynarski W., Mirowski M., Robak T. Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDR1 gene in a sample of Polish population. Pol J Pharmacol 2002; 54: 495–500
   PubMedGoogle Scholar
• Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y., et al. Expression of P‐glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)‐1 gene. J Pharmacol Exp Ther 2001; 297: 1137–43
   PubMed Web of Science ®Google Scholar
• Altman D. G. Practical statistics for medical research. Chapman & Hall, London 1997
   Google Scholar
• Lobenberg R., Amidon G. L. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 2000; 50: 3–12
   PubMed Web of Science ®Google Scholar
• Lacarelle B., Rahmani R., de Sousa G., Durand A., Placidi M., Cano J. P. Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes. Fundam Clin Pharmacol 1991; 5: 567–82
   PubMed Web of Science ®Google Scholar
• Chan L. M., Lowes S., Hirst B. H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 2004; 21: 25–51
   PubMed Web of Science ®Google Scholar
• Gerloff T., Schaefer M., Johne A., Oselin K., Meisel C., Cascorbi I., et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002; 54: 610–6
   PubMed Web of Science ®Google Scholar
• Westphal K., Weinbrenner A., Giessmann T., Stuhr M., Franke G., Zschiesche M., et al. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P‐glycoprotein. Clin Pharmacol Ther 2000; 68: 6–12
   PubMed Web of Science ®Google Scholar
• Hinderling P. H., Garrett E. R., Wester R. C. Pharmacokinetics of beta‐methyldigoxin in healthy humans II: oral studies and bioavailability. J Pharm Sci 1977; 66: 314–25
   PubMed Web of Science ®Google Scholar
• Cummins C. L., Wu C. Y., Benet L. Z. Sex‐related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P‐glycoprotein. Clin Pharmacol Ther 2002; 72: 474–89
   PubMed Web of Science ®Google Scholar
• Efferth T. Adenosine triphosphate‐binding cassette transporter genes in ageing and age‐related diseases. Ageing Res Rev 2003; 2: 11–24
   PubMed Web of Science ®Google Scholar
• Achira M., Suzuki H., Ito K., Sugiyama Y. Comparative studies to determine the selective inhibitors for P‐glycoprotein and cytochrome P4503A4. AAPS PharmSci 1999; 1: E18
   PubMed Web of Science ®Google Scholar
• Floren L. C., Bekersky I., Benet L. Z., Mekki Q., Dressler D., Lee J. W., et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 41–9
   PubMed Web of Science ®Google Scholar
• Litman T., Zeuthen T., Skovsgaard T., Stein W. D. Competitive, non‐competitive and cooperative interactions between substrates of P‐glycoprotein as measured by its ATPase activity. Biochim Biophys Acta 1997; 1361: 169–76
   PubMed Web of Science ®Google Scholar
• Taipalensuu J., Tavelin S., Lazorova L., Svensson A. C., Artursson P. Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1‐dependent drug efflux activity. Eur J Pharm Sci 2004; 21: 69–75
   PubMed Web of Science ®Google Scholar
• Fromm M. F., Kauffmann H. M., Fritz P., Burk O., Kroemer H. K., Warzok R. W., et al. The effect of rifampicin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000; 157: 1575–80
   PubMed Web of Science ®Google Scholar